DBV Technologies reported $673.7M in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amarin USD 290M 51M Dec/2025
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
DBV Technologies USD 274M 17M Sep/2025
Esperion Therapeutics USD 885M 351M Dec/2025
Halozyme Therapeutics USD 7.66B 257M Mar/2026
Incyte USD 18.73B 660M Mar/2026
Insmed USD 35.3B 1.82B Mar/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
PTC Therapeutics USD 5.64B 460M Mar/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
United Therapeutics USD 25.19B 4.21B Mar/2026